You are here

Amgen

Founding Member

Robert A. Bradway

Chairman, CEO Roundtable on Cancer
Chairman of the Board, President and Chief Executive Officer, Amgen, Inc.

Robert A. Bradway is Amgen’s chairman and chief executive officer. Bradway became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company’s president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010. 

Prior to joining Amgen, he was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990. 

He is a member of the board of directors of The Boeing Company, serving on its Audit and Finance committees. Bradway serves on the board of trustees of the University of Southern California and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university. He is the chairman of the CEO Roundtable on Cancer, a non-profit organization comprised of executives founded to bring solutions to cancer treatment and prevention. He is also a member of the American Heart Association CEO Roundtable on Cancer, which is helping the Association meet its goal of improving the cardiovascular health of all Americans.

Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University.

CEO Roundtable on Cancer

Board of Directors

Chairman, CEO Roundtable on Cancer since 2015

CEO Cancer Gold Standard™

Gold Standard  Employer

Gold Standard Employer Since 2014 | Gold Standard - China Employer Since 2017

Quote

We are honored to join other leading organizations in the commitment to a healthy workforce as a CEO Cancer Gold Standard accredited corporation. Our mission at Amgen is to serve patients, especially those suffering from serious illness, which makes us acutely aware of the toll cancer can have on patients and their loved ones. In addition to numerous health and wellness programs for our staff members, Amgen supports educational programs and resources ranging from prevention to survivorship for those outside of our company who are affected by cancer.

— Robert A. Bradway

Gold Standard  Task Force Participation

Task Force Representative and Accreditation Review Board Member: Carole Mendoza, Executive Director of Global Benefits

Global Gold Standard  Task Force Participation

Global Gold Standard Subcommittee Member: Carole Mendoza, Executive Director of Global Benefits

Life Sciences Consortium

LSC  Task Force Participation

Life Sciences Consortium Co-Chair: David Reese MD, Executive Vice President of Research & Development

Task Force Members: Gregory Friberg MD, Global Product General Manager; Raymond C. Jordan, Senior Vice President & Corporate Affair

Project Data Sphere, LLC

an independent initiative of the Life Sciences Consortium

Data Provider

Since 2015

Communications Support for Project Data Sphere, LLC, 2016-2017

Further Support

Founding Member, CEO Roundtable on Cancer – China

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.